Institute of Cardiovascular Sciences We are leaders in cardiovascular research, including atrial fibrillation and heart failure, thrombosis and haemostasis, and vascular biology.
News Steep rise for Life Sciences and Medicine in QS World University Rankings The College of Medical and Dental Sciences achieves significant rises in subject rankings, according to latest figures.
News Dr Pavlovic appointed as Editor in Chief of the Journal of Molecular and Cellular Cardiology PLUS
QS World University Subject Rankings released for 2023 University of Birmingham rises 30 places to be joint 62nd in the world for Life Sciences and Medicine.
09 March 2023 Naturally occurring peptide may tackle the ‘root cause’ of obesity-related conditions Research shows the peptide called PEPITEM could provide a revolutionary approach to reducing the risk of type 2 diabetes and other obesity-related diseases
21 February 2023 Continue heart failure treatment despite initial kidney reduction, new guidelines suggest Summary of European Society of Cardiology report will direct both heart and kidney failure specialists to make best use of new treatments and prolong lives.
10 January 2023 Dr Pavlovic appointed as Editor in Chief of the Journal of Molecular and Cellular Cardiology PLUS JMCC PLUS publishes fundamental and translational research that advances knowledge of the mechanisms for normal and diseased cardiovascular function.
13 December 2022 Blood clotting research holds hope for sepsis Researchers who identified a novel mechanism for platelet activation in blood clotting (thrombosis) are now turning their attention to sepsis
12 December 2022 Heart surgery and impact on mental health among new priorities for congenital heart disease research Patients, parents, charities and healthcare professionals agree key focuses for future research for disease affecting around half a million in UK
02 December 2022 Abnormal heartbeat identified in 1 in 20 older adults using wrist-worn wearable and smartphone A new study, conducted by the Atrial Fibrillation NETwork (AFNET), offered smartphone and arrhythmia screening to older adults without atrial fibrillation.
23 November 2022 World’s first clinical trial to test new drug glenzocimab for heart attacks New partnership with Acticor Biotech will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.